What is the primary driver of the year-over-year increase in net sales?

The primary driver of the 12.4% increase in net sales to $296.8 million was strong performance in international markets, particularly in the Heart Valve Therapy and Critical Care segments. The launch of the Edwards SAPIEN transcatheter heart valve in Europe and continued growth in hemodynamic monitoring equipment were significant contributors.

Why did net income decrease significantly compared to the prior year's quarter?

Net income decreased from $33.2 million in Q1 2007 to $18.2 million in Q1 2008 primarily due to a $10.1 million "Special Charges, net" recorded during the quarter. This charge was mainly comprised of an $8.1 million loss on the sale of the LifeStent product line and a $2.1 million litigation settlement. Excluding these one-time charges, the underlying operational performance remained strong.

What is the company's strategy regarding its product lines, as indicated by recent divestitures and acquisitions?

The company is strategically focusing on its core heart valve and critical care businesses. This is evidenced by the divestiture of the LifeStent peripheral vascular product line in January 2008 and the acquisition of the CardioVations product line in December 2007. These moves aim to concentrate resources on high-growth cardiovascular areas.

What is the status of the PARTNER trial and its implications for future growth?

The PARTNER trial is a pivotal clinical trial for the Edwards SAPIEN transcatheter heart valve technology in the United States. Enrollment is ongoing for both high-risk surgical patients (Cohort A) and non-operable patients (Cohort B). The company anticipates completing enrollment for Cohort B by the end of 2008 and Cohort A by the end of Q3 2009. Positive results from this trial are crucial for potential FDA approval and future growth in the significant US market.

EW 10-Q Quarterly Report Q1 FY2008 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation reported its first quarter results for 2008, showcasing robust top-line growth driven by strong performance in its Heart Valve Therapy and Critical Care segments. Net sales increased by 12.4% year-over-year, reaching $296.8 million, boosted by international sales growth and the launch of new products like the Edwards SAPIEN transcatheter heart valve in Europe. While net income saw a decline from $33.2 million in Q1 2007 to $18.2 million in Q1 2008, this was primarily due to a significant "Special Charges, net" line item of $10.1 million, mainly related to the loss on the sale of the LifeStent product line and litigation settlement. The company's strategic focus on its core cardiovascular businesses appears to be paying off, with continued investment in research and development, particularly in transcatheter heart valve technologies. Despite the decrease in net income, the underlying operational performance, excluding special charges, indicates a positive trajectory. Investors should monitor the progress of the PARTNER trial for the SAPIEN valve in the US and the upcoming regulatory approvals in Japan and Europe, as these represent key growth drivers for the company.

Key Highlights

1Net sales increased 12.4% to $296.8 million, driven by strong international growth in Heart Valve Therapy and Critical Care.
2Heart Valve Therapy sales grew 13.3% to $146.7 million, fueled by the European launch of the Edwards SAPIEN transcatheter heart valve.
3Critical Care sales rose 17.4% to $106.7 million, with the FloTrac system and hemodynamic monitoring equipment showing significant gains.
4The company recorded a $10.1 million "Special Charges, net" in the quarter, largely due to an $8.1 million loss on the sale of the LifeStent product line.
5Net income decreased to $18.2 million ($0.31/diluted share) from $33.2 million ($0.54/diluted share) in the prior year period, primarily due to the special charges.
6The company repurchased $100.0 million of its common stock under its authorized repurchase program.
7Research and development expenses increased to $32.9 million, reflecting continued investment in transcatheter and surgical heart valve programs.

Edwards Lifesciences Corp Quarterly Report for Q1 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions